Literature DB >> 12739138

Effectiveness of rescue antiretroviral therapy including intravenously administered zidovudine and foscarnet in a child with HIV-1 enteropathy.

Marc Hainaut1, Michèle Gérard2, Cécile Alexandra Peltier3, Hichem Souayah3, Françoise Mascart4, Georges Zissis5, Jack Levy3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12739138     DOI： 10.1007/s00431-003-1224-9

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

3.  Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection.

Authors:  S Bergdahl; B Jacobsson; L Moberg; A Sönnerborg
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-05-01

4.  Foscarnet decreases HIV-1 plasma load.

Authors:  I Devianne-Garrigue; I Pellegrin; R Denisi; M Dupon; J M Ragnaud; P Barbeau; D Breilh; B Leng; H J Fleury; J L Pellegrin
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-05-01

5.  Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient.

Authors:  G Tachedjian; J Hoy; K McGavin; C Birch
Journal:  J Med Virol       Date:  1994-02       Impact factor: 2.327

6.  Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

Authors:  G Tachedjian; J Mellors; H Bazmi; C Birch; J Mills
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.